Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database
- 470 Downloads
The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data on monitoring and assessment of RCC targeted therapy on a national level.
KeywordsRenal cell carcinoma Targeted therapy Clinical registry Cancer care Database Population-based data
Authors would like to thank all cancer centres involved in data collection for the RenIS registry: University Hospital Brno—Otakar Bednařík, MD; St. Ann’s University Hospital, Brno—Jana Katolická, MD, PhD; Masaryk Memorial Cancer Institute, Brno—prof. Rostislav Vyzula, MD, PhD; Hospital České Budějovice—Václav Janovský, MD, Alena Šináklová, MD; University Hospital Hradec Králové—prof. Jiří Petera, MD, PhD, assoc.prof. Josef Dvořák, MD, PhD; Hospital Chomutov—Martina Chodacká, MD; Hospital Jihlava—Lubomír Slavíček, MD, Věra Benešová, MD; Regional Hospital Liberec—Jiří Bartoš, MD, MBA, Věra Hejzlarová, MD; Hospital and Health Centre in Nový Jičín—assoc. prof. Renata Soumarová, MD, PhD, MBA, Josef Gruna, MD; University Hospital Olomouc—prof. Bohuslav Melichar, MD, PhD, Petr Beneš, MD, PhD; University Hospital Ostrava—David Feltl, MD, PhD, Martina Vybíralová, MD; Regional Hospital Pardubice—assoc. prof. Jaroslav Vaňásek, MD, PhD, Iveta Kolářová, MD; University Hospital Plzeň—assoc. prof. Jindřich Fínek, MD, PhD, Vladimíra Arnetová, MD; Hospital Na Bulovce, Prague—Vladimíra Stáhalová, MD; Hospital Na Homolce, Prague—Martin Šafanda, MD, PhD; General University Hospital in Prague—prof. Luboš Petruželka, MD, PhD; University Hospital Motol, Prague—Jana Prausová, MD, PhD, Stanislav Batko, MD; Thomayer Hospital, Prague—prof. Jitka Abrahámová, MD, PhD; Masaryk Hospital in Usti nad Labem—Milan Lysý, MD, David Šulc, MD; T. Baťa Regional Hospital, Zlín—Milan Kohoutek, MD, Alena Jakšičová, MD. This work was supported by the Project MZ0MOU2005 of the Czech Ministry of Health. The RenIS registry is supported by research grants from Novartis, Pfizer, Bayer, Roche, and GlaxoSmithKline.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 (online). International Agency for Research on Cancer, Lyon, France, 2010. Available from: http://globocan.iarc.fr.
- 2.Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiology of malignant tumours in the Czech Republic (online). Masaryk University, Czech Republic. 2005. Available from: http://www.svod.cz. Version 7.0 , ISSN 1802-8861.
- 3.Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer incidence and mortality in the Czech Republic (in Czech). Klin Onkol. 2010;23(5):311-24.Google Scholar
- 11.Bergmann L, Kube U, Kindler M, Koepke T, Steiner G, Janssen J, et al. A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: results of a preplanned interim analysis of a prospective study. American Society of Clinical Oncology (ASCO) annual meeting; 3–7 June 2011; Chicago, Illinois, USA.Google Scholar
- 19.Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.Google Scholar
- 21.Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. Nov 5 2011 [Epub ahead of print].Google Scholar
- 22.Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011;60(6):1163–70.PubMedCrossRefGoogle Scholar